New combo pill for high blood pressure enters first human tests

NCT ID NCT07421375

Not yet recruiting Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new pill called BR1015-A, which combines two common blood pressure medicines (fimasartan and indapamide) into one tablet. The study will involve 58 healthy adult volunteers to see how the body absorbs and processes the drug, and to check for any safety issues. If results are good, this could lead to a simpler, once-daily treatment option for people with high blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BR1015-A (combination of fimasartan and indapamide)
What this could lead to: If successful, this could lead to a new once-daily pill that combines two blood-pressure-lowering drugs, making treatment simpler and more effective for people with hypertension.
What could go wrong: This is a very early (Phase 1) study in only 58 healthy volunteers, not patients. It is designed to check safety and how the drug moves through the body, not whether it actually works for hypertension. Many early-stage drugs do not make it to market.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.